These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 33800723)

  • 1. Lipidated Peptidomimetic Ligand-Functionalized HER2 Targeted Liposome as Nano-Carrier Designed for Doxorubicin Delivery in Cancer Therapy.
    Naik H; Sonju JJ; Singh S; Chatzistamou I; Shrestha L; Gauthier T; Jois S
    Pharmaceuticals (Basel); 2021 Mar; 14(3):. PubMed ID: 33800723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lyophilized liposomal formulation of a peptidomimetic-Dox conjugate for HER2 positive breast and lung cancer.
    Sonju JJ; Shrestha P; Dahal A; Gu X; Johnson WD; Zhang D; Muthumula CMR; Meyer SA; Mattheolabakis G; Jois SD
    Int J Pharm; 2023 May; 639():122950. PubMed ID: 37059241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultrasound-mediated cavitation enhances the delivery of an EGFR-targeting liposomal formulation designed for chemo-radionuclide therapy.
    Thomas E; Menon JU; Owen J; Skaripa-Koukelli I; Wallington S; Gray M; Mannaris C; Kersemans V; Allen D; Kinchesh P; Smart S; Carlisle R; Vallis KA
    Theranostics; 2019; 9(19):5595-5609. PubMed ID: 31534505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell-penetrating corosolic acid liposome as a functional carrier for delivering chemotherapeutic drugs.
    Li X; Widjaya AS; Liu J; Liu X; Long Z; Jiang Y
    Acta Biomater; 2020 Apr; 106():301-313. PubMed ID: 32081779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pH-sensitive liposome formulation of a peptidomimetic-Dox conjugate for targeting HER2 + cancer.
    Sonju JJ; Dahal A; Singh SS; Gu X; Johnson WD; Muthumula CMR; Meyer SA; Jois SD
    Int J Pharm; 2022 Jan; 612():121364. PubMed ID: 34896567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor targeting using anti-her2 immunoliposomes.
    Park JW; Kirpotin DB; Hong K; Shalaby R; Shao Y; Nielsen UB; Marks JD; Papahadjopoulos D; Benz CC
    J Control Release; 2001 Jul; 74(1-3):95-113. PubMed ID: 11489487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GE11-modified liposomes for non-small cell lung cancer targeting: preparation, ex vitro and in vivo evaluation.
    Cheng L; Huang FZ; Cheng LF; Zhu YQ; Hu Q; Li L; Wei L; Chen DW
    Int J Nanomedicine; 2014; 9():921-35. PubMed ID: 24611009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aptamer-drug conjugate: targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicity.
    Dou XQ; Wang H; Zhang J; Wang F; Xu GL; Xu CC; Xu HH; Xiang SS; Fu J; Song HF
    Int J Nanomedicine; 2018; 13():763-776. PubMed ID: 29440899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual-Ligand-Functionalized Liposomes Based on Glycyrrhetinic Acid and cRGD for Hepatocellular Carcinoma Targeting and Therapy.
    Qiu M; Wang J; Bai J; Li X; Tian C; Liu Z; Zheng C; Clark AR; Cheng X; Liao X; Wu S; Lee RJ; Zhou X
    Mol Pharm; 2023 Apr; 20(4):1951-1963. PubMed ID: 36952242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel Diosgenin-Based Liposome Delivery System Combined with Doxorubicin for Liver Cancer Therapy.
    Chen L; Lan J; Li Z; Zeng R; Wang Y; Zhen L; Jin H; Ding Y; Zhang T
    Pharmaceutics; 2022 Aug; 14(8):. PubMed ID: 36015311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Folate and TAT peptide co-modified liposomes exhibit receptor-dependent highly efficient intracellular transport of payload in vitro and in vivo.
    Zhu Y; Cheng L; Cheng L; Huang F; Hu Q; Li L; Tian C; Wei L; Chen D
    Pharm Res; 2014 Dec; 31(12):3289-303. PubMed ID: 24858397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced Cytotoxicity of Folic Acid-Targeted Liposomes Co-Loaded with C6 Ceramide and Doxorubicin: In Vitro Evaluation on HeLa, A2780-ADR, and H69-AR Cells.
    Sriraman SK; Pan J; Sarisozen C; Luther E; Torchilin V
    Mol Pharm; 2016 Feb; 13(2):428-37. PubMed ID: 26702994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation of a PEGylated liposome that co-encapsulates l-arginine and doxorubicin to achieve a synergistic anticancer effect.
    Feng H; Kang JH; Qi S; Kishimura A; Mori T; Katayama Y
    RSC Adv; 2021 Oct; 11(54):34101-34106. PubMed ID: 35497323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A liposomal radionanoformulation for targeted drug delivery and real time monitoring by radionuclide imaging for HER2 overexpressing cancers.
    Suman SK; Mukherjee A; Sharma RK
    Drug Dev Res; 2023 Nov; 84(7):1553-1563. PubMed ID: 37578143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liposomal Doxorubicin: the Sphingomyelin/Cholesterol System Significantly Enhances the Antitumor Efficacy of Doxorubicin.
    Meng X; Zhang H; Chen L; Wang M; Zhang K; Liu X; Deng Y; Song Y
    AAPS PharmSciTech; 2023 Feb; 24(2):64. PubMed ID: 36759405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Novel Long-circulating DOX Liposome: Formulation and Pharmacokinetics Studies.
    Xiao P; Zhao J; Huang Y; Jin R; Tang Z; Wang P; Song X; Zhu H; Yang Z; Yu N
    Pharm Nanotechnol; 2020; 8(5):391-398. PubMed ID: 32787769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index.
    Scomparin A; Salmaso S; Eldar-Boock A; Ben-Shushan D; Ferber S; Tiram G; Shmeeda H; Landa-Rouben N; Leor J; Caliceti P; Gabizon A; Satchi-Fainaro R
    J Control Release; 2015 Jun; 208():106-20. PubMed ID: 25869964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of Dual-Loaded Doxorubicin and Sorafenib Liposomes Co-Modified with Glycyrrhetinic Acid and Cell-Penetrating Peptide TAT.
    Su H; Tu Z; Jing L; Huang Y; Liu X; Yuan M
    Curr Drug Deliv; 2024 Sep; ():. PubMed ID: 39230001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.
    Zahmatkeshan M; Gheybi F; Rezayat SM; Jaafari MR
    Eur J Pharm Sci; 2016 Apr; 86():125-35. PubMed ID: 26972276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functionalized nanoscale β-1,3-glucan to improve Her2+ breast cancer therapy: In vitro and in vivo study.
    Nasrollahi Z; Mohammadi SR; Mollarazi E; Yadegari MH; Hassan ZM; Talaei F; Dinarvand R; Akbari H; Atyabi F
    J Control Release; 2015 Mar; 202():49-56. PubMed ID: 25597638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.